NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over ID6394

Provisional Stakeholder List

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
Company • CSL Behring (garadacimab) Patient/carer groups • Action for Children • Allergy UK • Anaphylaxis Campaign • Asthma and Lung UK • Genetic Alliance UK • HAE UK • Immunodeficiency UK • Jnetics • NARA- The Breathing Charity • National Children's Bureau • South Asian Health Foundation • Specialised Healthcare Alliance Healthcare professional groups • Association for Respiratory Technology and Physiology • Association of Genetic Nurses & Counsellors • Association of Paediatric Emergency Medicine • British Geriatrics Society • British Paediatric Allergy, Immunity and Infection Group (BPAIIG) • British Paediatric Respiratory Society • British Skin Foundation • British Society for Allergy & Clinical Immunology • British Society for Genetic Medicine • British Society for Haematology • British Society for Immunology • British Thoracic Society	General • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health - Northern Ireland • Healthcare Improvement Scotland • Hospital Information Services – Jehovah's Witnesses • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Confederation • Scottish Medicines Consortium • Welsh Government • Welsh Health Specialised Services Committee Possible comparator companies • BioCryst Pharmaceuticals (berotralstat) • CSL Behring (Berinert) • Maxwellia (tranexamic acid) • Mylan (tranexamic acid) • Pharming Group N.V (Ruconest) • Rivopharm (tranexamic acid) • Sovereign Medical (tranexamic acid) • Takeda (Cinryze, lanadelumab) • Tillomed Laboratories (tranexamic acid) Relevant research groups • Asthma, Allergy and Inflammation Research Trust

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
• ILD-IN: Interstitial Lung Diseases Interdisciplinary Network • Immunology and Allergy Nurses Group • National Heart and Lung Institute • Neonatal and Paediatric Pharmacists Group • Primary Care Respiratory Society UK • Royal College of General Practitioners • Royal College of Nursing • Royal College of Paediatrics & Child Health • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • Royal Society of Medicine - Allergy and Immunology Section • UK Clinical Pharmacy Association • UK Forum on Haemoglobin Disorders <u>Others</u> • Department of Health and Social Care • NHS England	• British Association for Lung Research • Cochrane Airways Group • David Hide Asthma and Allergy Research Centre • Genomics England • MRC Clinical Trials Unit • National Institute for Health Research <u>Associated Public Health groups</u> • Public Health Wales • UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

<u>Consultees</u>

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.